Eurofins | Transplant Diagnostics

Three Leaders in Transplant Testing.
One Name

Together, Donor & Product Testing, Transplant Genomics and Viracor are Eurofins Transplant Diagnostics.

Learn More

Pre-Transplant

Critical donor screenings to ensure the overall health of the transplant donor. Microbiology testing aimed at reducing microorganisms that could compromise the transplant recipient. HLA testing to match donors and recipients. Eurofins Transplant Diagnostics is the go-to for pre-transplant testing solutions.

Learn More

Post Transplant & Infectious Disease Management

From solid organ transplant testing to blood and marrow transplant testing, over 75% of transplant programs across the U.S. turn to Eurofins Transplant Diagnostics. Whether assessing pre-transplant or identifying post-transplant, our solutions span the spectrum.

Learn More

Rejection Biomarkers

Through molecular diagnostic tests that detect issues and enable optimization of therapy and non-invasive genomic biomarker monitoring, Eurofins Transplant Diagnostics is the leader in testing designed to improve long-term outcomes.

Learn More

Your Partner for Every Step of the Transplant Journey

From donor to recipient, the transplant journey requires the right testing at the right time. That’s exactly what we deliver. Diagnostics that inform, monitor and lead to predictive analysis for patients and clinicians seeking personalized insights that can answer life and organ saving transplant questions.

Webinars

Register and view Webinar

Innovative Clinical Diagnostics: Leveraging Torque Teno Virus (TTV) in Transplant Management

Watch this on-demand webinar where we'll explore the significance of TTV in clinical settings and its potential as an objective aid for modifying immunosuppression in transplant recipients. Discover the latest diagnostic tools and methodologies that utilize TTV, along with real-world examples showcasing its impact on patient outcomes. The session will also include an interactive Q&A. Don't miss this opportunity to enhance your understanding of TTV in transplant care!

Watch the Webinar featuring Gaurav Gupta, MD

Register & View
Register and view Webinar

Medical Mycology 2024: What's New

Join us for an insightful presentation by Dr. Luis Ostrosky-Zeichner, MD, where we explore the latest advancements and emerging trends in the field of medical mycology. The discussion covers critical topics such as current epidemiological data, evolving nomenclature standards, and recent innovations in antifungal treatments. Additionally, the video delves into the necessity for new diagnostic methods to keep pace with novel drugs and examines the evolving practices in clinical trial conduct. Join us for a comprehensive update on where medical mycology stands today and what the future holds.

Watch the Webinar featuring Luis Ostrosky, MD

Register & View
Register and view Webinar

All About OmniGraf™ Liver

Transplant Genomics is proud to announce the release of OmniGraf™ Liver, the first and only non-invasive diagnostic test that provides guidance for controlled reduction of immunosuppression to optimize therapy in liver transplant recipients.

This innovative test provides a score for patients to assess their risk of rejection. OmniGraf™ Liver grades a patient on their risk for rejection, providing a numerical output for patients at high or low risk inclusive of patients that match the phenotype of acute dysfunction of the liver without the presence of rejection. Utilizing molecular biomarkers and advanced bioinformatics, OmniGraf™ Liver also allows for the controlled reduction of immunosuppressant therapy in three easy steps. OmniGraf™ Liver features a negative predictive value of 93%, internally validated using patient data from the CTOT-14 trial.

Watch the Webinar featuring our Vice President of Research and Development, Dr. Steve Kleiboeker, explain the science behind the test, and what to expect with this innovation!

Register & View
Register and view Webinar

Treating Subclinical Rejection Series

Watch this important webinar on Treating Subclinical Rejection featuring Dr. John Friedewald, Dr. Michael Marvin, and Dr. Namita Singh, as they delve into the complexities of treating subclinical rejection in kidney transplantation.

This webinar offers a unique opportunity to gain insights from a panel of experts who bring a wealth of knowledge and experience to the table. Together, they will explore the latest advancements in identifying and managing subclinical rejection, drawing from their combined expertise in both research and clinical practice.

Register & View
Eurofins Viracor Podcast

For Hematology/Oncology patients the ExPeCT anti-CD19 (FMC63) CAR T assay provides interventional data which may provide information on the expansion and persistence of the genetically modified T-cells used as therapeutic treatment for specific lymphomas and leukemias (Chimeric Antigen Receptor T-cell therapy or CAR T). Eurofins Viracor has developed and validated a multiplexed quantitative real-time PCR (qPCR) assay targeting FMC63 for the longitudinal monitoring of CD19-directed CAR T-cell therapy.

Ebook

Learn more about the different companies inside Eurofins Transplant

Learn More

Case Studies

Explore case studies featuring CMV inSIGHT™ T Cell Immunity testing.

Evaluate Neutropenic Transplant Recipient with CMV inSIGHT™ T Cell Immunity

Download

Molecular Biomarkers Guide Treatment and Prevent Rejection in Graft Monitoring

Long-Term Monitoring of Graft Health

Download

Please provide some basic information to access this content.